Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Jessica S.W. Borgers(The Netherlands Cancer Institute), Marit M. van Buuren(The Netherlands Cancer Institute), Michael S. Rooney(BioNTech (United States)), Vikram R. Juneja(Takara (United States)), John B.A.G. Haanen(Leiden University Medical Center), Matthijs D. Linssen(The Netherlands Cancer Institute), Mark DeMario(BioNTech (United States)), Divya Lenkala(BioNTech (United States)), Gauri Mahimkar(BioNTech (United States)), Sofie Wilgenhof(The Netherlands Cancer Institute), Sebastian Hymson(BioNTech (United States)), Sebastian Klobuch(The Netherlands Cancer Institute), Cynthia M. Nijenhuis(The Netherlands Cancer Institute), Xi Chen(BioNTech (United States)), Christina M. Arieta(BioNTech (United States)), Ekaterina Esaulova, Yvonne Ware(BioNTech (United States)), Kristen N. Balogh(BioNTech (United States)), Inge Jedema(The Netherlands Cancer Institute), Johannes V. van Thienen(The Netherlands Cancer Institute), Joong-Hyuk Sheen(BioNTech (United States)), Bastiaan Nuijen(The Netherlands Cancer Institute), Tracey Sciuto(BioNTech (United States)), Olivia Finney(Seattle Children's Hospital), Suchitra Ramesh(BioNTech (United States)), Jesse Z. Dong(BioNTech (United States)), Claudia Gottstein(BioNTech (Germany)), Richard B. Gaynor(BioNTech (United States)), E Cosgrove(BioNTech (United States)), Brian J. McCarthy(United States Department of Health and Human Services), Kelledy Manson(Dana-Farber Cancer Institute), Emily Jackson(BioNTech (United States)), John Srouji(BioNTech (United States)), Victoria Kohler(BioNTech (United States)), Karina C. Scheiner(The Netherlands Cancer Institute), Kimberly Starr(BioNTech (Germany))
Cited by 40
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
|Journal of Clinical Investigation|2001|1.6k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999